Basic Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Dec 15, 2023; 15(12): 2120-2137
Published online Dec 15, 2023. doi: 10.4251/wjgo.v15.i12.2120
Hsa_circ_0136666 mediates the antitumor effect of curcumin in colorectal carcinoma by regulating CXCL1 via miR-1301-3p
Shi Chen, Wei Li, Chen-Gong Ning, Feng Wang, Li-Xing Wang, Chen Liao, Feng Sun
Shi Chen, Chen-Gong Ning, Feng Wang, Li-Xing Wang, Chen Liao, Feng Sun, Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, Yunnan Province, China
Wei Li, Department of Blood Transfusion, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, Yunnan Province, China
Co-first authors: Shi Chen and Wei Li.
Author contributions: Chen S and Li W contributed equally to this work and are co-first authors, including design of the study, acquiring and analyzing data from experiments, and writing of the actual manuscript. Chen S, Li W, Li W and Wang F conceived and designed the experiments; Liao C, Chen S, Wang F and Ning CG performed the research; Ning CG, Wang LX, and Sun F contributed to the statistical analysis; Chen S, Li W, Wang F and Ning CG wrote the paper; including design of the study, acquiring and analyzing data from experiments, and writing of the actual manuscript. All authors read and approved the final manuscript.
Supported by National Natural Science Foundation of China, No. 81960508; Yunnan Province Wang Bin Expert Workstation, No. 202205AF150011.
Institutional review board statement: This study did not involve any human studies.
Institutional animal care and use committee statement: The experimental protocol was approved by the Animal Care and Use Committee of The Second Affiliated Hospital of Kunming Medical University.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Feng Sun, PhD, Doctor, Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Kunming Medical University, No. 374 Yunnan-Myanmar Avenue, Wuhua District, Kunming 650101, Yunnan Province, China. sunfeng1971@163.com
Received: July 27, 2023
Peer-review started: July 27, 2023
First decision: August 8, 2023
Revised: September 22, 2023
Accepted: October 16, 2023
Article in press: October 16, 2023
Published online: December 15, 2023
Processing time: 140 Days and 1.9 Hours
Abstract
BACKGROUND

This study investigate the anti-tumor effect of curcumin and whether its mediated by hsa_circ_0136666 through miR-1301-3p/CXCL1 in colorectal carcinoma (CRC). Through multiple experiments, we have drawn the conclusion that curcumin inhibited CRC development through the hsa_circ_0136666/miR-1301-3p/CXCL1 axis, hinting at a novel treatment option for curcumin to prevent CRC development.

AIM

To determine whether hsa_circ_0136666 involvement in curcumin-triggered CRC progression was mediated by sponging miR-1301-3p.

METHODS

Cell counting kit-8, colony-forming cell, 5-ethynyl-2’-deoxyuridine, and flow cytometry assays were carried out to determine cell proliferation, apoptosis, and cell cycle progression. Real-time quantitative polymerase chain reaction quantified hsa_circ_0136666, miR-1301-3p, and chemokine (C-X-C motif) ligand 1 (CXCL1), and western blot analysis determined CXCL1, B-cell lymphoma-2 (Bcl-2), and Bcl-2 related X protein (Bax) protein levels. CircBank or starbase software was first used for the prediction of miR-1301-3p binding with hsa_circ_0136666 and CXCL1, followed by RNA pull-down, RNA immunoprecipitation, and dual-luciferase reporter assay validation. In vivo experiments were implemented in a murine xenograft model.

RESULTS

Curcumin blocked CRC cell proliferation but boosted apoptosis. Moreover, elevated hsa_circ_0136666 Levels were observed in CRC cells, which were reduced by curcumin. In vitro, hsa_circ_0136666 overexpression abolished the antitumor activity of CRC cells. Mechanical analysis revealed the ability of hsa_circ_0136666 to sponge miR-1301-3p to modulate CXCL1 levels.

CONCLUSION

Curcumin inhibited CRC development through the hsa_circ_0136666/miR-1301-3p/CXCL1 axis, hinting at a novel treatment option for curcumin to prevent CRC development.

Keywords: Curcumin; Hsa_circ_0136666; MiR-1301-3p; CXCL1; Colorectal carcinoma

Core Tip: This study investigate the anti-tumor effect of curcumin and whether its mediated by hsa_circ_0136666 through miR-1301-3p/CXCL1 in colorectal carcinoma (CRC). Through multiple experiments, we have drawn the conclusion that curcumin inhibited CRC development through the hsa_circ_0136666/miR-1301-3p/CXCL1 axis, hinting at a novel treatment option for curcumin to prevent CRC development.